Risankizumab for previously treated moderately to severely active Crohn's disease

  • Technology appraisal guidance
  • TA888
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

September 2024: In section 2, we updated the list prices for the 600‑mg concentrate for solution for injection and the on-body device with 360‑mg solution for injection.

November 2023: In section 2, we removed information on CE-marking for the on-body device that delivers the 360‑mg risankizumab solution for injection because the CE mark has now been granted.